Browsing Tag
Sintilimab
2 posts
Dizal Pharmaceutical deepens NSCLC pipeline case as DZD6008 and golidocitinib data sharpen ASCO 2026 focus
Read how Dizal’s ASCO 2026 NSCLC data for DZD6008 and golidocitinib could reshape its lung cancer pipeline strategy today!
May 31, 2026
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
June 5, 2025